Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Osteoarthritis (OA) of the Knee

PHASE2TerminatedINTERVENTIONAL
Enrollment

241

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Pain
Interventions
DRUG

AZD1386

oral, during 4 weeks

DRUG

AZD1386

oral, during 4 weeks

DRUG

Placebo

Oral, during 4 weeks

Trial Locations (41)

Unknown

Research Site, Pleven

Research Site, Sofia

Research Site, Bay Roberts

Research Site, St. John's

Research Site, Halifax

Research Site, Brampton

Research Site, Etobicoke

Research Site, Hamilton

Research Site, Newmarket

Research Site, St. Catharines

Research Site, Charlottetown

Research Site, Saint Romuald

Research Site, Sherbrooke

Research Site, Helsinki

Research Site, Hyvinkää

Research Site, Lahti

Research Site, Riihimäki

Research Site, Tampere

Research Site, Vantaa

Research Site, Békéscsaba

Research Site, Budapest

Research Site, Debrecen

Research Site, Miskolc

Research Site, Nyíregyháza

Research Site, Veszprém

Research Site, Japan

Research Site, Bialystok

Research Site, Elblag

Research Site, Gdynia

Research Site, Krakow

Research Site, Lublin

Research Site, Toru

Research Site, Warsaw

Research Site, Brastislava

Research Site, Komárno

Research Site, Liptovský Hrádok

Research Site, Poprad

Research Site, Považská Bystrica

Research Site, Rimavská Sobota

Research Site, Žiar nad Hronom

Research Site, Žilina

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY